Susumu Hijioka, MD, PhD, discusses the efficacy of first-line everolimus plus lanreotide in patients with unresectable or recurrent GEP-NETs.
Susumu Hijioka, MD, PhD
Advertisement
Susumu Hijioka, MD, PhD, works in the Department of Hepatobiliary and Pancreatic Oncology at National Cancer Center, in Japan.
Articles by Susumu Hijioka, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
4
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
5